{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADVAIR+250%2F50mcg", "query": { "intervention": "ADVAIR 250/50mcg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADVAIR+250%2F50mcg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T01:59:49.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00346749", "title": "ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Salmeterol", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol Combination Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 180, "start_date": "2006-12", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00346749" }, { "nct_id": "NCT00568347", "title": "Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COPD" ], "interventions": [ { "name": "fluticasone 100mcg/ salmeterol 50mcg", "type": "DRUG" }, { "name": "fluticasone 250/salmeterol 50", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "salmeterol and fluticasone propionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arthur F Gelb MD", "sponsor_class": "INDIV", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "20 Years to 85 Years" }, "enrollment_count": 39, "start_date": "2006-01", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00568347" }, { "nct_id": "NCT00633217", "title": "Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Propionate/Salmeterol DISKUS 250/50mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 247, "start_date": "2008-03", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 16, "location_summary": "Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Sunset", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633217" }, { "nct_id": "NCT00452348", "title": "A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID", "type": "DRUG" }, { "name": "Fluticasone propionate 250 mcg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 628, "start_date": "2007-05", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2016-12-09", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fresno, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452348" }, { "nct_id": "NCT01110200", "title": "Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "ADVAIR DISKUS 250/50 mg BID", "type": "DRUG" }, { "name": "SEREVENT 50 mcg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 639, "start_date": "2010-04-30", "completion_date": "2012-05-08", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110200" }, { "nct_id": "NCT01475721", "title": "SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "ADVAIR 100/50mcg", "type": "DRUG" }, { "name": "ADVAIR 250/50mcg", "type": "DRUG" }, { "name": "ADVAIR 500/50mcg", "type": "DRUG" }, { "name": "FLOVENT 100mcg", "type": "DRUG" }, { "name": "FLOVENT 250mcg", "type": "DRUG" }, { "name": "FLOVENT 500mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 11751, "start_date": "2011-11-18", "completion_date": "2015-06-23", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 350, "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475721" }, { "nct_id": "NCT00784550", "title": "A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Tiotropium Bromide", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "40 Years to 99 Years" }, "enrollment_count": 342, "start_date": "2008-12", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2016-11-23", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 35, "location_summary": "Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Naranja", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784550" }, { "nct_id": "NCT00857766", "title": "A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "ADVAIR DISKUS™ 250/50mcg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 249, "start_date": "2009-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00857766" }, { "nct_id": "NCT00144911", "title": "ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Salmeterol", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol Combination Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 740, "start_date": "2004-10", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00144911" }, { "nct_id": "NCT00115492", "title": "Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Propionate/Salmeterol Combination Product", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 797, "start_date": "2004-12", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-20T01:59:49.242Z", "location_count": 95, "location_summary": "Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00115492" } ] }